Hydroxyamphetamine

CHEMBL1546 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
151.2 g/mol
LogP
1.4
Phase
4

This sympathomimetic agent works by releasing stored norepinephrine from nerve endings, and is primarily used as eye drops to dilate the pupil (mydriasis) for diagnostic eye examinations. It helps doctors examine the back of the eye without requiring more potent agents.

Berat Molekul

151,2100 g/mol

LogP

1,40

TPSA

46,30 Ų

Lipinski RO5

Lulus

Mekanisme Kerja

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(N)Cc1ccc(O)cc1

InChI

InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3

Molecular Formula

C9H13NO

HBD / HBA

2 / 2

Ikatan yang Dapat Dirotasi

2

Atom Berat

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This sympathomimetic agent works by releasing stored norepinephrine from nerve endings, and is primarily used as eye drops to dilate the pupil (mydriasis) for diagnostic eye examinations. It helps doctors examine the back of the eye without requiring more potent agents.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Hydroxyamphetamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1546. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3651. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.